Target and tissue selectivity of PROTAC degraders.
Guenette RG, Yang SW, Min J, Pei B, Potts PR.
Chem Soc Rev. 2022 Jul 18;51(14):5740-5756. doi: 10.1039/d2cs00200k.
Target-Directed Approaches for Screening Small Molecules against RNA Targets.
Haniff HS, Knerr L, Chen JL, Disney MD, Lightfoot HL.
SLAS Discov. 2020 Sep;25(8):869-894. doi: 10.1177/2472555220922802. Epub 2020 May 18.
Target-directed catalytic metallodrugs.
Joyner JC, Cowan JA.
Braz J Med Biol Res. 2013 Jun;46(6):465-85. doi: 10.1590/1414-431X20133086. Epub 2013 Jul 2.
Emerging Target Families: Intractable Targets.
Knapp S.
Handb Exp Pharmacol. 2016;232:43-58. doi: 10.1007/164_2015_28.
Chasing molecular glue degraders: screening approaches.
Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C.
Chem Soc Rev. 2022 Jul 4;51(13):5498-5517. doi: 10.1039/d2cs00197g.
Emerging Targets in Non-Small Cell Lung Cancer.
Liu L, Soler J, Reckamp KL, Sankar K.
Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046.
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I, Verrecchia F, Crenn V, Redini F, Trichet V.
Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976.
Genome engineering with zinc-finger nucleases.
Carroll D.
Genetics. 2011 Aug;188(4):773-82. doi: 10.1534/genetics.111.131433.
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T.
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. doi: 10.1038/s41392-020-00449-4.
Targeted Drug Delivery: Trends and Perspectives.
Ashique S, Sandhu NK, Chawla V, Chawla PA.
Curr Drug Deliv. 2021;18(10):1435-1455. doi: 10.2174/1567201818666210609161301.
